Recent Quotes (30 days)

You have no recent quotes
chg | %

Cascadian Therapeutics Inc (USA) news

   Watch this stock
Showing stories 1 - 10 of about 85   

Articles published

CASC 4.35 0.00 (0.00%)
price chart
Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on ...
SEATTLE, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter financial results after the close of the U.S. financial markets ...
Cascadian Therapeutics (CASC): Positive Momentum for Metastatic Breast ...  Equities.com
Cascadian Therapeutics Announces Changes to Board of Directors
SEATTLE, March 13, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Robert W. Azelby has been appointed to the Company's Board of Directors. Mr. Azelby is ...
What Will Happen to Cascadian Therapeutics Incorporated (NASDAQ:CASC) Next ...
... growth factor receptor 2 inhibitor. More notable recent Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) news were published by: Seekingalpha.
Volume for Cascadian Therapeutics, Inc. (CASC) is down on the average volume ...  NY Stock News
Cascadian Therapeutics Inc (USA) (CASC) EPS Estimated At $-0.28  BZ Weekly
Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to ...
SEATTLE, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has granted orphan drug designation to ...
25 Stocks Moving In Wednesday's Pre-Market Session  Benzinga
Cascadian Therapeutics' (CASC) CEO Scott Myers On Q2 2017 Results - Earnings ...
Good day, ladies and gentlemen, and welcome to the Cascadian Therapeutics Second Quarter 2017 Financial Results Conference Call.
Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in ...
“Our interactions with regulators in the U.S. and Europe continue to support the design of our pivotal trial as a registrational pathway for tucatinib in both regions,” said Marc Lesnick, Ph.
Cascadian Therapeutics' Lead Candidate, Tucatinib, Receives Orphan Drug ...
SEATTLE, June 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib, an investigational oral, small molecule kinase inhibitor that is highly selective for ...
Cascadian Therapeutics: Worth Much More Than The Present Share Price
Despite misgivings about management, the company possesses a promising clinical candidate in tucatinib that is worth much more than the present valuation.
Cascadian Therapeutics (USA) (CASC) Analysts See $-0.28 EPS; Papa Johns ...
Papa John's International, Inc. operates and franchises pizza delivery and carryout restaurants and, in certain international markets, dine-in and delivery restaurants under the trademark Papa John's.
Company in Focus: Watching Shares of Cascadian Therapeutics Inc (CASC)
Investors may be studying some short-term indicators on shares of Cascadian Therapeutics Inc (CASC). The current 7-day average directional indicator is Buy.